Department of Pharmacy, Huaihe Hospital, Henan University, Kaifeng, China.
Department of Cardiology, Huaihe Hospital, Henan University, Kaifeng, Henan, China.
Sci Rep. 2023 Jan 31;13(1):1715. doi: 10.1038/s41598-022-26654-5.
In spite of similar efficacy and safety in pilot studies, compared with the contemporary durable polymer drug-eluting stent (DP-DES), the bioabsorbable polymer drug-eluting stent (BP-DES) may be more superior in promoting blood vessel healing. We sought to compare the safety and efficacy of everolimus-eluting BP-DES (BP-EES) with contemporary DP-DES through a meta-analysis. We performed this meta-analysis to provide further evidence of the safety and efficacy of BP-EES. Medline, Embase and the Cochrane library databases were searched for randomized controlled trials comparing clinical efficacy and safety of BP-EES versus contemporary DP-DES. Fifteen RCTs with a total of 15,572 patients were selected. The rate of MACE was 9.4% in patients receiving BP-EES and 7.3% receiving DP-EES (RR 1.13, 95% CI 0.99-1.29, p = 0.05; I = 46%). TLF and MI were also similar in both groups. Based on the available data, this review demonstrates that BP-EES displays a clinically comparable efficacy and safety profile to that of contemporary DP-DES at years of follow-up in patients undergoing PCI.
尽管在试点研究中具有相似的疗效和安全性,但与当代持久聚合物药物洗脱支架(DP-DES)相比,可吸收聚合物药物洗脱支架(BP-DES)在促进血管愈合方面可能更具优势。我们通过荟萃分析比较了依维莫司洗脱 BP-DES(BP-EES)与当代 DP-DES 的安全性和疗效。我们进行这项荟萃分析是为了提供更多关于 BP-EES 安全性和疗效的证据。我们在 Medline、Embase 和 Cochrane 图书馆数据库中检索了比较 BP-EES 与当代 DP-DES 临床疗效和安全性的随机对照试验。共选择了 15 项 RCT,共有 15572 名患者。接受 BP-EES 治疗的患者的 MACE 发生率为 9.4%,接受 DP-EES 治疗的患者为 7.3%(RR 1.13,95%CI 0.99-1.29,p=0.05;I=46%)。TLF 和 MI 在两组中也相似。根据现有数据,本综述表明,在 PCI 患者的随访年中,BP-EES 显示出与当代 DP-DES 临床疗效和安全性相当的疗效。